Tourmaline Bio Net Cash Flow 2020-2025 | TRML

Tourmaline Bio net cash flow from 2020 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.

Tourmaline Bio Net Cash Flow 2020-2025 | TRML

Tourmaline Bio net cash flow from 2020 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$81.6B
Zoetis (ZTS)$65.1B
Daiichi Sankyo, - (DSNKY)$45.7B
Takeda Pharmaceutical (TAK)$45.2B
BeOne Medicines - (ONC)$33.7B
Sandoz Group AG (SDZNY)$25B
Summit Therapeutics (SMMT)$21.6B
Merck (MKKGY)$16.2B
Shionogi (SGIOY)$14.9B
United Therapeutics (UTHR)$13.7B
Neurocrine Biosciences (NBIX)$12.7B
Orion OYJ (ORINY)$11.7B
IPSEN (IPSEY)$10.8B
Madrigal Pharmaceuticals (MDGL)$7.5B
Corcept Therapeutics (CORT)$7.4B
Grifols, S.A (GRFS)$7.3B
Stevanato Group S.p.A (STVN)$7B
Ionis Pharmaceuticals (IONS)$6.9B
Hikma Pharmaceuticals Plc (HKMPF)$5.9B
Ono Pharmaceutical (OPHLF)$5.2B
Soleno Therapeutics (SLNO)$4.1B
Hypermarcas (HYPMY)$2.9B
Crinetics Pharmaceuticals (CRNX)$2.7B
Catalyst Pharmaceuticals (CPRX)$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.5B
Procaps Group, S.A (PROCF)$2.5B
NewAmsterdam Pharma (NAMS)$2.4B
Centessa Pharmaceuticals (CNTA)$2.3B
Ocular Therapeutix (OCUL)$1.9B
Endo (NDOI)$1.8B